Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-08-06 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025
Share Issue/Capital Change Classification · 1% confidence The document is an HKEX FF301 Monthly Return for Equity Issuer, detailing movements in authorised and issued share capital, exercises of share options, placements/subscriptions, and confirmations under the Listing Rules. It is a routine regulatory submission reporting changes to the company’s capital structure (new shares issued, share option exercises, etc.). This aligns with our definition for Share Issue/Capital Change (SHA): announcements regarding new share issues or other capital changes. Therefore, SHA is the correct classification.
2025-08-06 English
Monthly Return
Regulatory Filings Classification · 1% confidence The document is a monthly return submission (Form FF301) to the Hong Kong Exchanges and Clearing Limited under Chapter 19B of the Listing Rules, detailing movements in authorised, registered, and issued share capital for the month. It is a compliance/regulatory filing rather than an annual or interim report, earnings release, capital issuance announcement, or any other more specific category. This type of formal listing‐rule return does not neatly fall under specialized categories and is therefore classified as a general Regulatory Filing (RNS).
2025-08-04 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a Hong Kong Exchange announcement by CStone Pharmaceuticals notifying the date of a Board meeting to consider and approve and publish its unaudited interim results and interim dividend for the six months ended June 30, 2025. It does not contain the actual financial report or results, nor is it a form of proxy, management discussion, or director change notice. It simply announces the timing of the Board meeting to publish the interim results, fitting the definition of a Report Publication Announcement (RPA).
2025-08-04 English
VOLUNTARY ANNOUNCEMENT - ESMO 2025: CSTONE TO DEBUT CS2009 CLINICAL DATA AND CS5001 TRIAL DESIGN
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by CStone Pharmaceuticals regarding upcoming clinical data presentations at an oncology conference (ESMO 2025). It does not contain financial results, voting outcomes, board changes, share transactions, or other specific regulated content. It is not an earnings release, annual/interim report, or detailed investor presentation, nor is it a notice of dividend or capital change. As a general business update outside the scope of other defined categories, it falls into the fallback category of Regulatory Filings (RNS).
2025-07-28 English
ANNOUNCEMENT ON RESULTS OF THE ISSUANCE OF THE 2025 FIRST TRANCHE OF SUPER-SHORT-TERM BONDS
Capital/Financing Update Classification · 1% confidence The document is an announcement by Yankuang Energy Group regarding the successful issuance of its 2025 first tranche of super-short-term bonds, detailing the amount, terms, interest rate, bookrunner, and underwriters. This is a financing update about the company’s capital raising activity (bond issuance), which falls squarely under the Capital/Financing Update category.
2025-07-25 English
PUBLICATION OF THE PRODUCTION AND SALES VOLUME FOR THE SECOND QUARTER OF 2025 OF AN OVERSEAS SUBSIDIARY CONTROLLED BY YANKUANG ENERGY GROUP COMPANY LIMITED
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Yankuang Energy Group providing operational data (production and sales volumes and prices) for Q2 and first half 2025 of a controlled overseas subsidiary. It is not a full interim or annual financial report, not an earnings release (which would focus on profits, revenues, EPS), nor a report publication notice (the data itself is included). It does not fall under any other specific categories like dividends, M&A, share issues, ESG, etc. Therefore it defaults to the general regulatory announcements fallback category: RNS.
2025-07-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.